SCHEMBL4676341

SCHEMBL4676341

O=C(C=C(O)c1nc[nH]n1)c1cnn(Cc2ccccn2)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 1/20 0.41
ERCC5 P28715 1/20 0.37
SLC40A1 Q9NP59 2/20 0.36
KDM5B Q9UGL1 1/20 0.36
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
RPS6KA3 P51812 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
HDAC1 Q13547 1/20 0.34
TAS2R8 Q9NYW2 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ALKBH2 Q6NS38 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
KLKB1 P03952 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678760 0.87 KLKB1 (0.41) ALDH1A1L3MBTL1KLKB1
SCHEMBL4672787 0.85 CREBBP (0.41) CREBBPERCC5SLC40A1KDM5BKDM4E
SCHEMBL4672090 0.83 KLKB1 (0.38) ERCC5KDM5BKDM4EALDH1A1TSHR
SCHEMBL4673045 0.83 ALDH1A1 (0.46) KDM5BKDM4EALDH1A1MAPTKDM4C
SCHEMBL4674052 0.82 KDM4C (0.40) KDM4EALDH1A1MAPTTSHRMAPK1
SCHEMBL4674971 0.81 MARS1 (0.39) KDM4EALDH1A1MAPTTSHRMAPK1
SCHEMBL4671994 0.81 KDM4E (0.40) KDM4EALDH1A1MAPTKLKB1
SCHEMBL4674940 0.80 KLKB1 (0.42) KDM4EALDH1A1KLKB1
SCHEMBL4676208 0.80 KDM4E (0.34) KDM4EALDH1A1MAPTTSHRMAPK1
SCHEMBL4672069 0.80 LMNA (0.43) CREBBPKDM4EALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CREBBP 3384/4885ERCC5 2718/4885SLC40A1 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.